Somagenics Looks to Partner microRNA-detection Tech as Therapeutics Efforts Continue | GenomeWeb

In an bid to tap a growing interest in using microRNAs as biomarkers of disease or tissue injury, Somagenics has developed a platform for detecting the small, non-coding RNAs in circulation.

Somagenics hopes the platform, called miR-Direct, will attract the attention of an industry partner interested in commercializing it. Meanwhile, the company is continuing to press ahead with its efforts in RNAi therapeutics with a focus on wound healing after pulling back on its hepatitis C program in the wake of advances made by other drugmakers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.